IL-1 is the primary proinflammatory cytokine responsible for autoinflammatory disorders, including RP,5 and therefore, blocking IL-1 activity was hypothesised to provide therapeutic benefit in RP. This evidence concerns the gene IL1A and retinitis pigmentosa 1.